APA (7th ed.) Citation

Thomas, L., de la Cruz, C. G., Mata-Martín, C., González-Rodríguez, I., González-Martínez, I., Peñas-Lledó, E. M., & LLerena, A. (2026). Influence of CYP2D6 , CYP2C19 , and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients. Pharmaceuticals (14248247), 19(2), 209. https://doi.org/10.3390/ph19020209

Chicago Style (17th ed.) Citation

Thomas, Levin, Carla González de la Cruz, Carmen Mata-Martín, Idian González-Rodríguez, Idilio González-Martínez, Eva M. Peñas-Lledó, and Adrián LLerena. "Influence of CYP2D6 , CYP2C19 , and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients." Pharmaceuticals (14248247) 19, no. 2 (2026): 209. https://doi.org/10.3390/ph19020209.

MLA (9th ed.) Citation

Thomas, Levin, et al. "Influence of CYP2D6 , CYP2C19 , and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients." Pharmaceuticals (14248247), vol. 19, no. 2, 2026, p. 209, https://doi.org/10.3390/ph19020209.